The stock finished 10.66% below its 52-week high of $28.75 reached on 2 April, while trading volume of 36.8 million was below its 50-day average.
Among peers, Johnson & Johnson, Eli Lilly and Abbott Laboratories also fell, though Pfizer was described as underperforming in an otherwise strong broader market session.
Is Pfizer's high dividend a safe bet for investors or a gamble against its massive pipeline needs?
Is Pfizer's billion-dollar bet on obesity a brilliant comeback or too little, too late against market giants?
With key patents expiring, can Pfizer's new oncology drugs fill the massive revenue gap in time?